HLTRF News and Press, HLS Therapeutics Inc From 02/27/20

HLS Therapeutics to Host Q4 and Fiscal 2019 Financial Results Conference Call Canada NewsWire TORONTO, Feb. 27, 2020 TORONTO , Feb. 27, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervo...

HLS Therapeutics ( OTCPK:HLTRF ) announces that Vascepa (icosapent ethyl) will be available in Canada on or about February 18. More news on: HLS Therapeutics Inc., Amarin Corporation plc, Healthcare stocks news, Read more ...

HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl) Canada NewsWire TORONTO, Jan. 28, 2020 Vascepa to be available on or about February 18, 2020 , supported by a national Cardiovascular salesforce Vascepa becomes the ...

HLS Therapeutics Files New Drug Submission for PERSERIS® in Canada Canada NewsWire TORONTO, Jan. 23, 2020 If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia TORONTO ...

HLS Therapeutics Announces 8 Years of Data Protection for Vascepa® Canada NewsWire TORONTO, Jan. 6, 2020 Peak-year sales estimate increases to CAD$200 -300 million, from CAD$150 -250 million Commercial launch expected to take place in the mid-February 2020 ...

HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events Canada NewsWire TORONTO, Dec. 31, 2019 Health Canada approval follows priority review for Vascepa Vascepa becomes the first and only HC-approved medica...

Agenus (NASDAQ: AGEN ) resumed with Buy rating and $6 (36% upside) price target at B. Riley FBR. Shares up  1%  premarket. More news on: Agenus Inc., Cabaletta Bio, Inc., Geron Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa Canada NewsWire TORONTO, Nov. 15, 2019 TORONTO , Nov. 15, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervo...

HLS Therapeutics ( OTCPK:HLTRF ): Q3 GAAP EPS of -$0.06. More news on: HLS Therapeutics Inc., Earnings news and commentary, Tech stocks news, Read more ...

HLS Therapeutics Announces Q3 2019 Financial Results Canada NewsWire TORONTO, Nov. 7, 2019 Revenue of $13.4 million , Adjusted EBITDA of $8.0 million and Cash from Operations of $6.8 million Paid a quarterly dividend of C$0.05 per outstanding common share Su...